Porton Biopharma expands cancer drug manufacturing capacity

pharmafile | February 2, 2016 | News story | Manufacturing and Production, Research and Development Erwinase 

UK Life Sciences Minister George Freeman yesterday opened a new multi-million pound pharmaceutical manufacturing facility at Wiltshire-based Porton Biopharma Limited (PBL), increasing the capacity of the existing facility used for the production of cancer drug Erwinase.

Erwinase (asparaginase) treats acute lymphoblastic leukaemia (ALL), the most common form of cancer in children. The drug is registered in 22 countries, and was approved by the US FDA in November 2011.

George Freeman comments: “This impressive new facility on the Porton Campus has the potential to make a significant contribution to the local economy and to UK life sciences – a sector which has seen £6 billion of investment and created 17,000 jobs since 2011.  Not only will it help to drive the innovation and growth of the future, it will also produce life-enhancing treatments for the benefit of NHS patients.” 

Dr Roger Hinton, managing director of PBL, says: “I am delighted that the minister with our local MP John Glen, have been so supportive in helping PBL to seek to grow the business which is essential in enabling us to produce greater quantities of life-saving products and to support jobs in the local community.”

Advertisement

John Glen MP adds: “PBL will play an essential future role in the regional economy and to help generate prosperity within Salisbury, along with other local initiatives such as the Porton Science Park.” 

Joel Levy

Related Content

No items found
The Gateway to Local Adoption Series

Latest content